Tumor mutational burden as a predictive biomarker for molecularly matched therapy in two independent pan-cancer cohorts

被引:0
|
作者
Jelas, I [1 ]
de Bortoli, T. [2 ]
Benary, M. [2 ]
Horak, P. [3 ]
Lamping, M. [2 ]
Schaefer, R. [2 ]
Klauschen, F. [2 ]
Tinhofer-Keilholz, I [2 ]
Leyvraz, S. [2 ]
Keller, U. [2 ]
Stenzinger, A.
Froehling, S. [3 ]
Stintzing, S. [1 ,4 ]
Kurzrock, R. [5 ]
Keilholz, U. [2 ]
Rieke, D. [2 ]
机构
[1] Charite Univ Med Berlin, Klin Hamatol Onkol & Tumorimmunol, Berlin, Germany
[2] Charite Univ Med Berlin, Berlin, Germany
[3] NCT Heidelberg, Heidelberg, Germany
[4] Univ Klinikum Heidelberg, Heidelberg, Germany
[5] Worldwide Innovat Network WIN Assoc WIN Consortiu, Villejuif, France
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
V563
引用
收藏
页码:89 / 90
页数:2
相关论文
共 50 条
  • [21] Human pan-cancer analysis of the predictive biomarker for the CDKN3
    Chen, Yingjun
    Li, Dai
    Sha, Kaihui
    Zhang, Xuezhong
    Liu, Tonggang
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2024, 29 (01) : 272
  • [22] Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer
    Kim, Hongsik
    Kim, Hana
    Kim, Ryul
    Jo, Hyunji
    Kim, Hye Ryeon
    Hong, Joohyun
    Park, Joon Oh
    Park, Young Suk
    Kim, Seung Tae
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2021, 20
  • [23] Pan-cancer profiling of the effect of biopsied site on tumor mutational burden measurements in a real-world data cohort
    Papillon-Cavanagh, Simon
    Gao, Chuan
    Han, G. Celine
    Walsh, Alice M.
    CANCER RESEARCH, 2020, 80 (16)
  • [24] Predictive 'biomarker piggybacking': an examination of reflexive pan-cancer screening with pan-TRK immunohistochemistry
    Sholl, Lynette M.
    Zheng, Mei
    Nardi, Valentina
    Hornick, Jason L.
    HISTOPATHOLOGY, 2021, 79 (02) : 260 - 264
  • [25] Pan-cancer population pharmacokinetics and exposure-safety and -efficacy analyses of atezolizumab in patients with high tumor mutational burden
    Shemesh, Colby S.
    Chan, Phyllis
    Legrand, Fatema A.
    Shames, David S.
    Das Thakur, Meghna
    Shi, Jane
    Bailey, Lorna
    Vadhavkar, Shweta
    He, Xian
    Zhang, Wei
    Bruno, Rene
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2020, 8 (06):
  • [26] Unveiling the interplay between mutational signatures and tumor microenvironment: a pan-cancer analysis
    Luo, Li-Zhi
    Li, Sheng
    Wei, Chen
    Ma, Jiao
    Qian, Li-Mei
    Chen, Yan-Xing
    Wang, Shi-Xiang
    Zhao, Qi
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [27] Pan-cancer analysis of YAP1 expression as a predictive biomarker for cancer immunotherapy
    Owonikoko, Taofeek K.
    Elliott, Andrew
    Ivanov, Andrey
    Dwivedi, Bhakti
    Walker, Phillip
    Vanderwalde, Ari M.
    Puri, Sonam
    Dacic, Sanja
    Morgensztern, Daniel
    Liu, Stephen V.
    Borghaei, Hossein
    Sica, Gabriel
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] Pan-cancer analysis identifies SPEN mutation as a predictive biomarker with the efficacy of immunotherapy
    Ya-Dong Li
    Hao Huang
    Zheng-Ju Ren
    Ye Yuan
    Hao Wu
    Chuan Liu
    BMC Cancer, 23
  • [29] Pan-cancer analysis identifies SPEN mutation as a predictive biomarker with the efficacy of immunotherapy
    Li, Ya-Dong
    Huang, Hao
    Ren, Zheng-Ju
    Yuan, Ye
    Wu, Hao
    Liu, Chuan
    BMC CANCER, 2023, 23 (01)
  • [30] An integrative evaluation of circadian gene TIMELESS as a pan-cancer immunological and predictive biomarker
    Yaocheng Yang
    Xianzhe Tang
    Zhengjun Lin
    Tao Zheng
    Sheng Zhang
    Tang Liu
    Xiaolun Yang
    European Journal of Medical Research, 28